AMISTAD II, a larger trial enrolling >2,000 patients within 6 h of an anterior MI randomized to a 3-h infusion of either low-dose (50 mg/kg/min) or highdose (70 mg/kg/min) adenosine or placebo, found no difference in the primary endpoint of the study (new heart failure or death within 6 months). A substudy consisting of 243 patients designed to measure infarct size observed no effect on infarct size in the pooled adenosine groups; however, the high-dose adenosine group had a significant reduction in infarct size versus placebo (3). Post-hoc analysis of AMISTAD II observed improved outcomes in the subset of patients undergoing reperfusion within the first 3 h of infarction (4). Other randomized clinical trials using an intracoronary bolus of adenosine found no benefit (5,6). Thus, despite some "positive" findings, these clinical trials were essentially negative.
Adenosine is not used routinely for this purpose nor is it recommended by current practice guidelines. From the Cardiac Catheterization Laboratories, University of Virginia Health System, Charlottesville, Virginia. Dr. Ragosta has reported that he has no relationships relevant to the contents of this paper to disclose. there may be additional risk during a prolonged infusion. Prolonged infusion will also occupy the cardiac catheterization laboratory for many hours; it is unlikely that it will be safe to do this outside of the lab for fear of catheter dislodgment or vessel injury.
Finally, the timing of adenosine administration relative to symptom onset and reperfusion remains to be determined. As alluded to earlier, there may be only a very narrow window of benefit limited to patients undergoing successful reperfusion 2 to 6 h after symptom onset, but this needs additional careful study. So, although I applaud the perseverance and excellent work of Yetgin et al. (7), I doubt that intracoronary adenosine will become routine therapy after successful reperfusion therapy during acute MI any time soon.
REPRINT REQUESTS AND CORRESPONDENCE: Dr. Michael Ragosta, Cardiac Catheterization Laboratories, University of Virginia Health System, Charlottesville, Virginia 22909. E-mail: mr8b@virginia.edu.
